Debiopharm and Alkyon link for radioligand therapies development
The partnership will use Debiopharm's AbYlink conjugation tech in combination with Alkyon’s modular antibody platform.
Therapy Area
BioNTech bolsters mRNA pipeline with $1.25bn CureVac acquisition
Vaccine sceptics among new members hired by RFK Jr for CDC’s vaccine panel
Enterome to advance EO2463 immunotherapy with $19m funding
Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs
FDA approves Capsida’s CAP-003 gene therapy for Parkinson’s
Gilead hit with FDA clinical hold for batch of HIV trials
Echosens and Boehringer expand partnership for MASH diagnosis
